Literature DB >> 15292389

Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

Chiara Brignole1, Fabio Pastorino, Danilo Marimpietri, Gabriella Pagnan, Angela Pistorio, Theresa M Allen, Vito Pistoia, Mirco Ponzoni.   

Abstract

BACKGROUND: Expression of the c-myb proto-oncogene in neuroblastoma, the most common extracranial solid tumor of infancy, is linked with cell proliferation and differentiation. Neuroblastoma can be selectively targeted via monoclonal antibodies against the disialoganglioside (GD2) tumor-associated antigen. Liposomes coated with anti-GD2 antibodies (targeted liposomes) and entrapping a c-myb antisense oligonucleotide have antitumor activity. Because antisense oligonucleotides containing CpG motifs can stimulate immune responses, we evaluated the effect of CpG-containing c-myb antisense oligonucleotides encapsulated within targeted liposomes.
METHODS: Antisense (myb-as) and scrambled (myb-scr) control oligonucleotides with CpG motifs were encapsulated within GD2-targeted and non-targeted liposomes. Two murine (nude and SCID-bg) xenograft models of neuroblastoma were established. Mice (groups of 10) were injected intravenously with various oligonucleotide and liposome formulations, and life span, long-term survival, immune cell activation, and cytokine release were measured over time.
RESULTS: Tumor-bearing mice injected with targeted liposome-CpG-myb-as or targeted liposome-CpG-myb-scr lived longer than mice in any other group, although long-term survival (i.e., more than 120 days) was obtained only in mice injected with targeted liposome-CpG-myb-as. Splenocytes isolated from mice injected with targeted liposome-CpG-myb-as contained activated macrophages, B cells, and natural killer (NK) cells, but only activated NK cells were associated with antitumor cytotoxic activity. In vivo immune cell activation was accompanied by the time-dependent increases in plasma levels of the cytokines interleukin 12 (IL-12; maximum level reached by 2 hours) and interferon gamma (IFN-gamma; maximum level reached by 18 hours) and was dependent on the oligonucleotide CpG motif. Ablation of macrophages or NK cells resulted in a loss of in vivo antitumor activity.
CONCLUSION: Immune cell activation, involving the time-dependent activation of macrophages and NK cells, contributes to the antitumor activity of targeted liposome-CpG-myb-as against neuroblastoma and could improve the effectiveness of antitumor targeted liposomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292389     DOI: 10.1093/jnci/djh221

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  19 in total

Review 1.  Anti-GD2 antibody therapy for GD2-expressing tumors.

Authors:  Fariba Navid; Victor M Santana; Raymond C Barfield
Journal:  Curr Cancer Drug Targets       Date:  2010-03       Impact factor: 3.428

2.  Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.

Authors:  Brandon S Brown; Tariq Patanam; Keyan Mobli; Christian Celia; Peter E Zage; Andrew J Bean; Ennio Tasciotti
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

3.  Common pitfalls in preclinical cancer target validation.

Authors:  William G Kaelin
Journal:  Nat Rev Cancer       Date:  2017-05-19       Impact factor: 60.716

Review 4.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

Review 5.  Anti-GD2 immunotherapy for neuroblastoma.

Authors:  Sameer Sait; Shakeel Modak
Journal:  Expert Rev Anticancer Ther       Date:  2017-08-14       Impact factor: 4.512

6.  Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients.

Authors:  Fabio Morandi; Maria Valeria Corrias; Isabella Levreri; Paola Scaruffi; Lizzia Raffaghello; Barbara Carlini; Paola Bocca; Ignazia Prigione; Sara Stigliani; Loredana Amoroso; Soldano Ferrone; Vito Pistoia
Journal:  Cancer Immunol Immunother       Date:  2011-06-10       Impact factor: 6.968

Review 7.  GD2-targeted immunotherapy and radioimmunotherapy.

Authors:  Konstantin Dobrenkov; Nai-Kong V Cheung
Journal:  Semin Oncol       Date:  2014-07-21       Impact factor: 4.929

Review 8.  Delivery of oligonucleotides with lipid nanoparticles.

Authors:  Yuhua Wang; Lei Miao; Andrew Satterlee; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2015-02-27       Impact factor: 15.470

9.  Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease.

Authors:  Monica Bacci; Annalisa Capobianco; Antonella Monno; Lucia Cottone; Francesca Di Puppo; Barbara Camisa; Margherita Mariani; Chiara Brignole; Mirco Ponzoni; Stefano Ferrari; Paola Panina-Bordignon; Angelo A Manfredi; Patrizia Rovere-Querini
Journal:  Am J Pathol       Date:  2009-07-02       Impact factor: 4.307

10.  Production and characterization of a recombinant single-chain antibody against Hantaan virus envelop glycoprotein.

Authors:  Jie Yang; Rui Chen; Junxia Wei; Fanglin Zhang; Yong Zhang; Lintao Jia; Yan Yan; Wen Luo; Yunxin Cao; Libo Yao; Jifeng Sun; Zhikai Xu; Angang Yang
Journal:  Appl Microbiol Biotechnol       Date:  2009-12-10       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.